Table of Contents Table of Contents
Previous Page  18 / 33 Next Page
Information
Show Menu
Previous Page 18 / 33 Next Page
Page Background

Efficacy of 2nd line

chemo post IO?

mPFS2 on

second-line

therapy

21.5

(

87.5% platinum-based)

versus

8.5

(

94.4% IO)

Rina Hui

et al, COSA 2017

0

3

6

9

1 2

1 5

1 8

2 1

2 4

2 7

3 0

3 3

0

1 0

2 0

3 0

4 0

5 0

6 0

7 0

8 0

9 0

1 0 0

T im e , m o n th s

P F S 2 , %

P e m b ro 1 5 4

1 3 4

1 1 7

1 0 8

9 6

8 0

7 3

6 4

3 8

1 2

3

0

C h e m o 1 5 1

1 2 2

1 0 0

6 4

5 7

4 2

3 5

2 5

1 3

7

2

0

N o . a t ris k

67.6%

41.8%

49.7%

19.0%

Events, n

HR (95% CI)

Pembrolizumab

73

0.46 (0.34

–0.62)

Chemotherapy

113

Median (95% CI)

21.5 mo (14.8 mo–NR)

8.5 mo (7.2–11.4 mo)